文献速递脊柱关节炎

基因代理的白细胞介素-13抑制与银屑病性疾病风险相关:一项孟德尔随机化研究

Genetically Proxied Interleukin-13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study.
PubMed 文献 · Arthritis Rheumatol · 2024-07-31

研究利用IL13基因编码变异rs20541作为白细胞介素-13抑制(IL-13i)的工具变量,在563,946人中与循环嗜酸性粒细胞计数在全基因组显著性水平相关,评估其与银屑病关节炎(PsA)和银屑病的遗传关联。结果显示基因代理的IL-13i与PsA风险升高相关(OR 37.39;95%CI 11.52-121.34;P=1.64×10^-9)及银屑病风险升高相关(OR 20.08;95%CI 4.38-92.01;P=1.12×10^-4),未发现与克罗恩病、溃疡性结肠炎、强直性脊柱炎或虹膜炎的一致关联。

要点

  • 基因代理的IL-13i与PsA风险升高相关(OR 37.39;95%CI 11.52-121.34)。
  • 基因代理的IL-13i与银屑病风险升高相关(OR 20.08;95%CI 4.38-92.01)。
  • 作者建议开具IL-13抑制剂处方的医生警惕这些不良事件。

核心结论

  • 研究提供支持性遗传证据表明IL-13i与PsA和银屑病风险升高相关。
  • 作者建议开具IL-13抑制剂的医生警惕这些不良事件。

研究设计与样本

  • 孟德尔随机化研究,使用IL13基因编码变异rs20541作为IL-13i的工具变量。
  • 暴露工具在563,946人中与循环嗜酸性粒细胞计数在全基因组显著性水平相关。
  • 结局遗传数据来自PsA、银屑病及相关脊柱关节炎特征研究,最多10,588例病例和209,287例对照。
  • 进行共定位分析以检查遗传混杂,并使用循环IgE作为生物标志物在测试集和独立遗传数据集中验证关联。
  • 还使用英国生物银行个体水平数据重复分析。

主要发现

  • 基因代理的IL-13i与PsA风险升高相关(OR 37.39;95%CI 11.52-121.34;P=1.64×10^-9)。
  • 基因代理的IL-13i与银屑病风险升高相关(OR 20.08;95%CI 4.38-92.01;P=1.12×10^-4)。
  • 未发现与克罗恩病、溃疡性结肠炎、强直性脊柱炎或虹膜炎的一致关联。
  • 共定位分析未显示银屑病性疾病存在强遗传混杂证据。
  • 使用循环IgE作为暴露、独立结局数据和个体水平数据均重复了结果。

临床怎么用

  • 作者认为,开具IL-13抑制剂的医生应警惕PsA和银屑病这些不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Inhibitors of the interleukin 13 (IL-13) pathway, such as dupilumab, are licensed for atopic dermatitis and asthma. Adverse events resembling psoriatic disease after dupilumab initiation have been reported, but evidence is limited to case reports with uncertain causality. We aimed to investigate whether genetically mimicked IL-13 inhibition (IL-13i) is associated with risk of psoriatic arthritis (PsA) and psoriasis. METHODS: We instrumented IL-13i using a protein-coding variant in the IL13 gene, rs20541, that is associated with circulating eosinophil count (biomarker of IL-13i) at genome-wide significance in a study of 563,946 individuals. Outcome genetic data were taken from studies of PsA, psoriasis, and related spondyloarthritis traits in up to 10,588 cases and 209,287 controls. Colocalization analysis was performed to examine genetic confounding. We additionally used circulating IgE as a biomarker to test whether associations were replicated, both in the test and in an independent genetic dataset. We also replicated analyses using individual-level data from the UK Biobank. RESULTS: Genetically proxied IL-13i was associated with increased risk of PsA (odds ratio [OR] 37.39; 95% confidence interval [95% CI] 11.52-121.34; P = 1.64 × 10-9) and psoriasis (OR 20.08; 95% CI 4.38-92.01; P = 1.12 × 10-4). No consistent associations were found for Crohn disease, ulcerative colitis, ankylosing spondylitis, or iritis. Colocalization showed no strong evidence of genetic confounding for psoriatic disease. Results were replicated using circulating IgE for the exposure, using independent outcome data and using individual-level data. CONCLUSION: We provide supportive genetic evidence that IL-13i is linked to increased risk of PsA and psoriasis. Physicians prescribing IL-13 inhibitors should be vigilant for these adverse events.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Zhao SS, Hyrich K, Yiu Z, et al. Genetically Proxied Interleukin-13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study. Arthritis Rheumatol. 2024. PMID: 38973570. doi:10.1002/art.42942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。